Brought to you by:
PROMISE III: Six-month data ‘reinforce’ case for TADV in no-option CLTI patients
Six-month outcomes among no-option chronic limb-threatening ischemia (CLTI) patients treated using transcatheter arterialization of the deep veins with the LimFlow system (Stryker/Inari Medical) in the PROMISE III trial showed a 81% rate of amputation-free survival. Principal investigator Daniel Clair, MD,…
Enduring PROMISE: Real-world outcomes study suggests results continue to flow from transcatheter arterialization of the deep veins
First retrospective analysis shows comparable outcomes data to those found in PROMISE II pivotal trial, authors report. The first post-approval multicenter analysis of so-called “no-option” chronic limb-threatening ischemia (CLTI) patients treated using a pioneering transcatheter arterialization of the deep veins…
Transcatheter arterialization of the deep veins: Comparative analysis probes whether emerging modality is worth pursuing
“We’re living in a new world order” when it comes to “no-option” chronic limb-threatening ischemia (CLTI) patients, says Anahita Dua, MD. In recent years, into this arena has stepped transcatheter arterialization of the deep veins (TADV), raising hopes of reducing…
Deep vein arterialization: Much remains to be learned but use poised to expand in patients with less severe ischemia
These remain early days for transcatheter arterialization of the deep veins (TADV) in the setting of patients with severe chronic limb-threatening ischemia (CLTI), says Daniel Clair, MD, one of the principal investigators in key clinical trials of the procedure, but…
Personalized postoperative anticoagulation needed to curb lower-limb amputations
“We’re going to see more and more amputations if we don’t figure out the right post procedure thromboprophylaxis regime ASAP,” Anahita Dua, MD, warned during a lecture on innovative approaches to preventing amputation at the Vascular Society of Great Britain…
PROMISE II 12-month data show durable outcomes with the LimFlow system in no-option CLTI patients
One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the LimFlow system (LimFlow) and that the procedure is safe and reproducible. Daniel Clair (Vanderbilt University Medical…
LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical. A press release details that, under the terms of the agreement, LimFlow will receive US$250 million in cash at closing and be eligible…
The top 10 most popular Vascular Specialist stories of September 2023
Last month, the most read stories from Vascular Specialist included data releases from the recent Midwestern Vascular Surgical Society (MVSS) using direct revascularization of segmental arteries to prevent spinal cord ischemia; a reflection on the crucial role of vascular nurses during…
FDA approves LimFlow system for ‘no-option’ CLTI patients
The Food and Drug Administration (FDA) today announced approval of LimFlow therapy—a novel and minimally invasive procedure designed to bypass blockages in arteries of the legs and restore blood flow for many thousands of people suffering from chronic limb-threatening ischemia…
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’ of deep vein arterialization in no-option CLTI patients
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia (CLTI) patients were today published in the New England Journal of Medicine (NEJM). The publication confirmed…